AI Article Synopsis
- Favipiravir is a selective antiviral that gained interest as a treatment for COVID-19, but its traditional synthesis involves complicated multi-step processes with low yields.
- A new, one-step method for making favipiravir has been developed, using direct fluorination with Selectfluor® in a more efficient and eco-friendly way, achieving a higher yield of 50%.
- This new process takes advantage of an ionic liquid (BF-BMIM) to overcome challenges faced in the standard methods, streamlining production without needing special catalysts or additives.
Article Abstract
Favipiravir is an important selective antiviral that emerged as an alternative against COVID-19 during the pandemic. Its synthesis has gained great interest and the conventional strategies proceed through multiple-step protocols (6-7 reaction steps), which involve, in addition, several drawbacks with global yields, lower than 34%. Herein, a simple, economical, eco-friendly and scalable (1 g) one-step protocol for the synthesis of favipiravir from the direct fluorination of the available 3-hydroxy-2-pyrazinecarboxamide with Selectfluor® is reported. The reaction proceeds easily in BF-BMIM through a simple operational work-up, affording the favipiravir with a yield of 50% without the need of a special catalyst/additive. The key point of the present strategy was the use of the ionic liquid of BF-BMIM, which helps to minimize the several chemical limitations derived from 3-hydroxy-2-pyrazinecarboxamide as a substrate for the direct Selectfluor-mediated fluorination. All these chemical reactivity aspects are also discussed in detail.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/d3ob00380a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!